Natu has a 60% weight in $STAA (@Psych_Bags) header
Natu has a 60% weight in $STAA (@Psych_Bags) profile picture

Retail investor. Portfolio size sub $400K, and I concentrate in hopes to build wealth. Core holdings: $STAA

Joined May 2024
Photo by Natu has a 60% weight in $STAA (@Psych_Bags)Photo by Natu has a 60% weight in $STAA (@Psych_Bags)Photo by Natu has a 60% weight in $STAA (@Psych_Bags)Photo by Natu has a 60% weight in $STAA (@Psych_Bags)Photo by Natu has a 60% weight in $STAA (@Psych_Bags)Photo by Natu has a 60% weight in $STAA (@Psych_Bags)Photo by Natu has a 60% weight in $STAA (@Psych_Bags)Photo by Natu has a 60% weight in $STAA (@Psych_Bags)Photo by Natu has a 60% weight in $STAA (@Psych_Bags)Photo by Natu has a 60% weight in $STAA (@Psych_Bags)
Replying to @Psych_Bags
My favorite stock to buy heading into 2026 is Insight Molecular Diagnostics $IMDX 🧬🧪. If you're looking for more information about the opportunity, my pitch is below:
1
1
1
4
4,202
The worst part of being retail is getting ghosted from IR. Could be small sample size, could be not knowing how to properly write email. Maybe adding a bogus investment LLC underneath my name would help the response rate
1
120
$IMDX To not hear that the package was resubmitted is the big downer this quarter. It's apparent this team was given a novice FDA partner throughout its prep phrase. So to me, it's not fair to blame management based on what they were guided to submit. It just doesn't add up-
1
1
140
Approval no sooner than mid-March, so no need to buy anytime soon before the big announcement :/
1
1
24
This was my #biopick2026, but perhaps better for #biopick2027. Turn up the baggie blues 🎷🎷🎷
2
26
☹☹☹
$IMDX Insight Molecular Diagnostics, launches public offering — Underwritten offering of common stock, with pre-funded warrants for some investors, and a 15% overallotment option — Lake Street Capital Markets is the sole managing underwriter, and it's done under an effective S-3 shelf — Money goes to working capital and R&D in transplantation — Risk: dilution, with no size or price disclosed, and the company flags FDA review of GraftAssureDx as a risk Not financial advice.
1
2
355
$RPID Rapid Micro Biosystems, to be acquired by Merck KGaA for $0.75 per share in cash — Structured as a tender offer for all outstanding shares, with a minimum tender condition — Expected to close in December 2026 — Total deal value and premium not disclosed, and the tender offer documents haven't been filed yet — Risk: the deal needs enough shares tendered and other closing conditions Not financial advice.
3
145
$NPCE I'm coining the phrase... You just got Pat Williams'd!!!
1
127
$DRT.TO breaking out... Peloton another notable that said we're now exempt to section 232, so consultants are in on recommending it... aluminum already 15% off its highs, too
83
$STAA The essence of the schizo bull thesis:
2
238
$NLH.v As expected... Great execution with 8% organic growth, but bottom line hindered by forex. Will be a great dip to buy if we tread lower throughout the winter imo. New divisions, key hires, & op leverage setting up for a great '27
$NLH.V (Nova Leap Health): Q3 2026 results - Revenue US$9.53M vs US$8.26M YoY (+15.3%); organic growth 8.2% - Adjusted EBITDA US$860,804 vs US$670,706 YoY (+28.3%) - Gross profit margin 39.9% vs 39.6% prior year; operating income US$645,562 vs US$418,553 YoY (+54.2%) - Record Q3 revenue and Adjusted EBITDA; TTM revenue US$34.86M, TTM Adjusted EBITDA US$2.79M both records - Net income US$333,771 vs US$426,171 YoY (-21.7%) on investments in new locations and service expansion - Generated ~US$500K free cash flow in Q3; cash US$1.94M; debt-to-TTM Adjusted EBITDA 1.21x Watch: whether organic growth and operating leverage continue into Q4, and if new location investments begin contributing to earnings
1
217
$STAA Curious to see our friends at Anatole lick their $50M wound from unsuccessful corporate engagement and repurchase a material stake
2
1
403
It's not coincidence that all of these hedgie rats are surrounding the castle now, so I expect to see more fireworks before the 10-K is filed
1
72
$IMDX Position remains unchanged at a measly 3% weight heading into earnings. I really want to believe it's parlayed with approval, but it's such a coin flip and not asymmetric
1
237
It doesn't make sense to poach Donnie if authorization is doomed, which gives further credit to why a raise hasn't happened yet. But it's just as likely that the SIR delays into '27, which is obviously why an approval announcement hasn't been made yet. I have dry powder ready...
1
42
$STAA One of the many questions from tonight... how is 30M not enough for finished goods? That's the accounting value at cost before selling price/mark up, right?? So I think they only have consignment for China distribution
1
2
286
$STAA shame to not see guidance reinstated, but love to see top line beat mgmt expectations again. Reassuring to see A/R and inventory wane, but I think we'd all like to see more for 4Q. Downticks in opex are great to see, too. Setting up for green skies in '27... 💹
$STAA Q3 2026: Net income $5.6m, EPS $0.11 Revenue $83.4m, down 12% YoY (up 21% ex-China deferral) Adj EBITDA $14.4m, $0.28/dil sh China sales $39.3m, down 30% YoY EMEA up 31% YoY U.S. sales $6.5m Cash $206.4m $50m buyback authorized
3
304